Background Seasonal malaria chemoprevention is used in 13 countries in the Sahel region
of Africa to prevent malaria in children younger than 5 years. Resistance of Plasmodium …

Background In 2012, seasonal malaria chemoprevention (SMC) was recommended as
policy for malaria control by the World Health Organization (WHO) in areas of highly …

Background Anti-malarial drug resistance in Kenya prompted two drug policy changes
within a decade: sulphadoxine-pyrimethamine (SP) replaced chloroquine (CQ) as the first …

Sulfadoxine-pyrimethamine (SP) resistance in Plasmodium falciparum has been
widespread across continents, causing the major hurdle of controlling malaria. Resistance is …

In eastern and southern Africa, there has been a rapid increase in the prevalence of alleles
with mutations in the Plasmodium falciparum dihydrofolate reductase gene (dhfr) associated …

Background Malaria is the major cause of morbidity and mortality in Angola. The most
vulnerable groups to Plasmodium falciparum infection are pregnant women and children …

Objectives Pregnancy-associated malaria (PAM) is a complex form of malaria. To prevent
PAM, several African countries have adopted intermittent preventive treatment with …

The Thailand-Cambodia border is the epicenter for drug-resistant falciparum malaria.
Previous studies have shown that chloroquine (CQ) and pyrimethamine resistance …

Sulfadoxine-resistant Plasmodium falciparum undermines malaria prevention with
sulfadoxine/pyrimethamine. Parasites with a highly resistant mutant dihydropteroate …

Both use of sulphadoxine‐pyrimethamine (SP) and SP‐resistance of Plasmodium
falciparum are increasing in sub‐Saharan Africa. Mutations in the P. falciparum …